Welcome to World Class Retina Care

Our practice was established in 1980 in central Phoenix. Since then, we have grown to include more than 35 locations throughout Arizona, providing improved access to the highest quality medical care. We are proud to have become Arizona’s largest and most experienced ophthalmology practice focused specifically on the diagnosis and management of the retina and vitreous.

At RCA, we believe in providing you with professional, attentive, and personal care while utilizing the latest technology and treatments. We accept new patients every day, and urgent or emergency referrals are seen the same day.

Find Your Location Today

Take charge of your eye health!

Making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. we encourage everyone to take charge of their eye health and preserve their sight by following some simple tips.

Click here for more!

Latest News From RCA

Pravin U. Dugel, MD: Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

October 08, 2019 01:15 ET | Source: Novartis International AG In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients1,2 Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the… Read More »

Pravin U. Dugel, MD: Touch Ophthalmology Congress Expert Interviews

Professor Pravin U. Dugel, MD Pravin Dugel, Clinical Professor at the Roski Eye Institute, University of Southern California, USA, provides his expert insight into key data presented at EURETINA 2019 and discusses the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD. Clinical Spotlight Why retinal fluid is important… Read More »

Pravin U. Dugel, MD: ReNeuron hails “clear signal” from retinitis pigmentosa trials

“Overall, the improvements to date represent a clear signal of efficacy in a patient population where inexorable disease progression is the norm,” the company said Clinical update and conference presentations “Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa ReNeuron Group plc (AIM: RENE), a global leader in the development… Read More »